Salvage Perioperative Interstitial High-Dose-Rate Interventional Radiotherapy (Brachytherapy) for Local Recurrences of the Chest Wall Following Mastectomy and Previous External Irradiation
by
Tamer Soror
1,2,*,†, 
Maggie Banys-Paluchowski
3,†,
Corinna Melchert
1,
Dirk Rades
1,
Achim Rody
3,
Kerstin Muras
3,
Meiting Xie
3 and
György Kovács
4 1
Radiation Oncology Department, University of Lübeck/UKSH-CL, 23562 Lübeck, Germany
2
Radiation Oncology Department, National Cancer Institute (NCI), Cairo University, Cairo 11796, Egypt
3
Department of Gynecology/Breast Unit, University Hospital Schleswig-Holstein Campus Lübeck, 23538 Lübeck, Germany
4
Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2023, 15(3), 614; https://doi.org/10.3390/cancers15030614
Submission received: 9 December 2022
/
Revised: 9 January 2023
/
Accepted: 13 January 2023
/
Published: 18 January 2023
(This article belongs to the Section Cancer Therapy)
Abstract
:Simple Summary
Breast cancer patients who were treated with mastectomy and postoperative external irradiation may suffer from tumor relapse in the chest wall. The local treatment of such conditions prevents complications such as ulceration, bleeding, infection, offensive odor, and major psychological stress. In this study, we investigated an approach combining both surgical removal of the tumor and implanting plastic tubes for postoperative interventional radiotherapy in the operated regions. After accurate and personalized computer-based 3-dimensional planning, a small computer remoted radioactive source is introduced through the tubes to re-irradiate the operated region. The procedure led to local control of the tumor in 82% of the patients in five years. A few patients (8.9%) suffered from severe but manageable complications during the follow-up period. We believe that this perioperative and interdisciplinary treatment may be a valid option to help locally recurrent and previously irradiated breast cancer patients as it offers good oncological results and a low rate of severe complications.
Abstract
(1) Background: To investigate the technical feasibility, safety, and efficacy of interstitial perioperative high-dose-rate interventional radiotherapy (HDR-IRT, brachytherapy) as a local salvage treatment combined with surgery for local chest wall recurrences following mastectomy and subsequent external beam radiation treatment (EBRT). (2) Methods: A retrospective analysis of 56 patients treated with interstitial HDR-IRT in combination with local surgery of a chest wall recurrence of breast cancer after previous treatment with mastectomy and EBRT from 2008 to 2020. (3) Results: Local recurrence following HDR-IRT was encountered in seven (12.5%) patients. The 1-year local recurrence-free survival (RFS), 3-year RFS, and 5-year RFS were 91%, 82%, and 82%, respectively. The 1-year overall survival (OS), 3-year OS, and 5-year OS was 85.5%, 58%, and 30%, respectively. Acute grade 1–2 radiation dermatitis was observed in 22 (39.3%) patients. Late ≥grade 3 toxicities were encountered in five (8.9%) patients. (4) Conclusions: Salvage perioperative interstitial high-dose-rate interventional radiotherapy (brachytherapy) combined with surgery seems to be an effective interdisciplinary management with acceptable treatment-related toxicity for local recurrences of the chest wall following mastectomy and previous external irradiation.
1. Introduction
Local and locoregional recurrences following mastectomy and external irradiation in locally advanced breast cancer patients remain a frequent clinical problem. The rate of local recurrence (LR) in the ten years after mastectomy and post-operative irradiation may be as low as 1.6% in node-negative disease or as high as 8.1% in node-positive breast cancer [1,2,3]. Without post-operative irradiation, the rate of LR may reach 26% [3]. Local recurrences may be accompanied by other nodal or distant metastases in about one-third of the patients [1]. Whether isolated or as a part of a metastatic disease, uncontrolled LR could present with pain, ulceration, bleeding, infection, offensive odor, and major psychological stress. Patients with uncontrolled LR will consequently suffer from impaired quality of life; 62% of such patients reported a severe impairment of all quality of life indices [1]. The chest wall is the most common site of locoregional recurrence, whether as an isolated recurrence or accompanied by regional nodal recurrence or by distant metastases [4].
Curative local treatment options are usually limited. Surgery for resectable LR may be a suitable option with the challenge of local tissue reconstruction. In locally advanced lesions, there is a significant risk of positive margins or even gross residual [1,2]. On the other hand, reirradiation with external beam radiation treatment (EBRT) carries a potential high risk of radiation toxicities such as brachial plexopathy, soft tissue or bone necrosis, lymphedema of the arm, severe chest wall fibrosis, and lung fibrosis [5,6,7]. Reirradiation with hyperthermia had acceptable results with 14% of late grade 3 or higher toxicities [8,9]. Using contact brachytherapy with surface molds in extreme hypofractionation, in a split-course technique, or in combination with hyperthermia has been investigated [10,11,12]. Unfortunately, contact brachytherapy with surface molds is mainly limited to skin metastases as the dose is usually prescribed to a maximum depth of 5 mm [10,11,12].
A combined approach of curative or debulking surgery with perioperative interstitial high-dose-rate interventional radiotherapy (HDR-IRT, brachytherapy) was rarely investigated [13,14]. HDR-IRT is a highly accurate and conformal technique of irradiation. The sharp dose gradient ensures sparing of the adjacent tissues and organs at risk (OAR). Therefore, HDR-IRT is considered a suitable salvage option for the reirradiation of locally recurrent tumors following previous EBRT [15,16,17].
This retrospective analysis investigates the technical feasibility, safety, and efficacy of perioperative HDR-IRT as a salvage local treatment combined with surgery for resectable local recurrences of the chest wall following mastectomy subsequent to EBRT. To our knowledge, this is by far the largest published cohort of patients for such a treatment approach.
2. Patients and Methods
2.1. Patients
We reviewed all medical records of patients who received salvage HDR-IRT from January 2008 to December 2020. Only patients who had a history of mastectomy and previous EBRT were included in the analysis. A multidisciplinary tumor board (MDTB) discussed the treatment decision for each patient individually. Eligible patients were restaged through a physical examination, laboratory investigations, radiographic and/or isotopic scans before treatment, and provided signed informed consent before treatment. All patients received complementary systematic treatments according to national guidelines based on the MDTB decision.
2.2. Interventional Radiotherapy (Brachytherapy)
At the time of the surgical resection of the LR, the interventional radiotherapy expert evaluated the anatomy situation and potential micro- or macroscopic residual tumor locations together with the surgeon. The macroscopic tumor bed was marked with metallic surgical clips. Interstitial plastic tubes were implanted and sutured to the tumor bed in single plane (monoplane implant) with minimum two-centimeter distance to the surgical margin on the skin. The tubes were kept parallel to each other with an interspacing distance of 8–12 mm over the target area. In case of needed surgical reconstruction, interstitial tubes were implanted afterwards but before final suture (Figure 1).
Thin-slice computed tomography (CT) was performed on the second or the third postoperative day and digitally forwarded into the treatment planning system (TPS). The three-dimensional (3D) reconstruction of the CT images was used for tubes reconstruction, volume definition, and dose planning/optimization on the TPS (Oncentra planning; Elekta Brachytherapy, Veenendaal, Netherlands). The clinical target volume (CTV) included the estimated tumor bed, the surgical clips, and a safety margin of 10–20 mm according to the size of the reported microscopic surgical margin and excluding the skin. A minimum distance (3–5 mm) was kept between the reference isodose line and the skin surface, as well as a maximum 10 mm distance between the lateral tube and the reference isodose line [14]. The radiation was started according to the type of surgery and condition of the patient usually 4–5 days after surgery and the prescribed dose was delivered in twice-daily consecutive fractions with a minimum 6 h interval. Figure 2 shows a sample of the 3D dose distribution.
2.3. Follow-up
Patients were regularly examined every 3 months for 3 years, then every 6 months for 2 years, then annually. Treatment-related toxicities were graded according to the common terminology criteria for adverse events 5.0.
2.4. Statistical Analysis
Results were reported as an absolute value, median with range, or as mean with standard deviation. Overall survival (OS) was defined from the end of HDR-IRT to the date of the last follow-up visit or to the date of death. Recurrence-free survival (RFS) was defined from the end of HDR-IRT to the date of the last follow-up visit or to the date of confirming a local recurrence. Probability estimates of RFS and OS were calculated using Kaplan–Meier analysis. Multivariable logistic regression analysis was performed in order to identify factors independently associated with local recurrence; patients with missing data were excluded from this analysis. Examined factors included age, T stage, initial lymph node status, histologic type, histologic grade, ER/PR status, Her2 status, surgical margin status, hormonal treatment, and chemotherapy treatment. Statistical analyses were performed using SPSS-V.20 (IBM-Corp. Armonk, NY, USA).
3. Results
3.1. Patient and Tumor Characteristics
We identified 56 patients who received salvage HDR-IRT for chest wall recurrences following mastectomy and previous external irradiation. Table 1 summarizes the patients and disease characteristics. The median initial age of patients at the time of diagnosis with breast cancer was 55 years (range: 31–72). Mastectomy was performed as the primary surgical operation in 43 (75.4%) patients, while in 14 (24.6%) patients, mastectomy was performed for LR in the breast. All patients had received previous EBRT as part of the primary treatment. The median dose of EBRT was 50.4 Gy (range: 40–60.4). The median interval between EBRT and HDR-IRT was 12.5 months (range: 7–288).
The median age of the patients at HDR-IRT was 70 years (range: 37–89). After local resection of the recurrence, five patients received an abdominal rotational flap to reconstruct the surgical defect. Latissimus dorsi myocutaneous flap was used in one patient. The LR was macroscopically resected in all patients. Five (8.9%) patients had microscopically positive margins.
3.2. HDR-IRT Treatment Characteristics
The median number of catheters inserted during the procedure was 6 (range: 4–16). The median clinical target volume (CTV) was 25.5 cc (range: 16–46). The median dose was 30 Gy (range: 25–36). Other dosimetry parameters are summarized in Table 2.
3.3. Treatment Outcome and Related Toxicities
The median follow-up time was 30.3 months (range: 0.9–124.4). Local recurrence following HDR-IRT was encountered in seven (12.5%) patients; in those seven patients, the median time to develop LR was 13.2 months (range: 1.3–89.3) following HDR-IRT. Only two of them (2/7) had positive surgical margin. The one-year (1-y) local recurrence-free survival (RFS), 3-y RFS, and 5-y RFS were 91%, 82%, and 82%, respectively (Figure 3). Multivariable analysis did not identify any risk factor predictive for local recurrence.
During follow-up, 28 (50%) patients died. Among dead patients, five patients had local recurrence (17.9%). Death resulted from progressive metastatic disease in 26 patients and unknown causes in 2 patients. The mean time of death for those two patients was 66.4 months after the HDR-IRT. Among living patients at the time of analysis, six patients had evidence of disease. Four of them had distant metastases with or without locoregional recurrence and two patients had only regional nodal recurrence. The one-year (1-y) overall survival (OS), 3-y OS, and 5-y OS were 85.5%, 58%, and 30%, respectively (Figure 3).
Acute radiation dermatitis grade 1 and 2 was observed in 22 (39.3%) patients. The recorded treatment-related late toxicities were mostly grade 1–2. Late skin toxicities (grade 1–2) were documented in 19 (33.9%) patients. Fourteen patients had grade 1–2 fibrosis, and three patients had fibrosis grade 3 in the HDR-IRT field. One patient had chronic wound complications and needed a skin graft. One patient developed localized soft-tissue necrosis along the pathway of one of the HDR-IRT catheters, which was surgically treated. The total number of observed late ≥ grade 3 toxicities was five (8.9%) (Table 3). Other late toxicities that were investigated and not observed included pathological rib fracture, radiation-induced lung disease, and radiation-induced heart disease.
4. Discussion
Although most patients with local recurrence will eventually suffer from distant metastases [1,2], aggressive local treatment is required to prevent local complications and deterioration in the quality of life [1,4]. Local treatment options following mastectomy and external irradiation are limited. Surgery is the primary local treatment option in resectable lesions. The rate of local recurrence following surgery is 20% [18], and the 5-year local recurrence-free rate is 51% [19]. In a multi-institutional review of repeated irradiation of the chest wall or the breast for recurrent breast cancer, the overall complete response rate was 57% among 81 patients with only 12 months median follow-up time [20]. In a recent study by Fattahi et al., reirradiation using photon +/− electrons or protons for chest wall recurrences to a median dose of 45 Gy resulted in 74.6% 2-year locoregional recurrence-free survival. The cohort included 72 patients who were curatively (38%) or postoperatively (62%) re-irradiated. After a median follow-up of 22 months, the rate of severe late toxicity (≥grade 3) was 13% [5].
In a large study by Oldenborg et al., hyperthermia was applied in addition to EBRT in order to sensitize tumor cells among 414 patients with irresectable locoregional recurrent breast cancers. The overall clinical response rate was 86%, and the rate of severe late toxicity (≥grade 3) was 24% [21]. In another study that included 169 patients treated with reirradiation plus hyperthermia for recurrent breast cancer en cuirasse, the overall clinical response rate was 72%. Late ≥grade 3 toxicity was recorded in 14% of patients [9].
Pulsed reduced dose rate (PRDR) EBRT delivers the radiation dose at a significantly lower dose rate, which is believed to reduce toxicity to normal tissue through increasing the sublethal damage repair of normal tissues [22]. Burr et al. analyzed the results of PRDR-EBRT for reirradiation of recurrent breast cancer. The 2-year locoregional recurrence-free survival was 73.8%. Among the 43 patients who were included in the analysis, 18.6% had grade 3 late toxicity [23].
Furthermore, the use of proton reirradiation for locally or locoregionally recurrent breast cancer was investigated in few reports with a small number of patients [5,24,25]. Furthermore, the studies of proton reirradiation included chest wall recurrences as well as breast or lymph node(s) recurrences. Therefore, solid conclusions regarding its use in the treatment of isolated chest wall recurrences could not be obtained [5,24,25].
Contact brachytherapy with surface molds with or without hyperthermia is predominantly used to treat skin metastases. Besson et al. evaluated 43 patients who were treated with 4–6 fractions of HDR-brachytherapy twice weekly to 24 Gy mean total dose. The 3-year in-field local control was 51% with 11.6% severe late toxicity [10]. Harms et al. treated 58 patients with pulsed-dose-rate (PDR) contact brachytherapy. All patients were treated with a split course of two fractions of 20 Gy. The 3-year local recurrence-free survival was 75%. The rate of severe late toxicity was 67% [12]. Auoragh et al. investigated the addition of hyperthermia to contact brachytherapy in 18 patients. The 5-year local recurrence-free survival was 56%, and 17% of the patients had severe late complications.
In a study by Niehoff et al., 32 patients were treated with both surgical resection and HDR or PDR interstitial brachytherapy. The PDR-brachytherapy mean dose was 30 Gy, and the HDR-brachytherapy mean dose was 28 Gy in twice-daily fractions. The mean follow-up time was 13 months. Local control was achieved in 20/32 patients. Only one patient experienced grade 3 late toxicity [14].
In the present study, we reported the results of salvage perioperative interstitial HDR-IRT for chest wall recurrences following mastectomy and previous external irradiation. Multimodal management that includes surgery for resectable lesions, radiation +/− hyperthermia, and possible systemic treatment may achieve a high rate of local control and could be curative in a subset of patients with an isolated chest wall recurrence [26]. In the current analysis, all treated lesions were macroscopically resected, and the HDR-IRT catheters were immediately intraoperatively implanted, which ensured an ideal estimation of the target volume. This combined approach aimed at maximum local control. The median dose of HDR-IRT was 30 Gy delivered in twice-daily fractions, which is a similar treatment approach to that reported by Niehoff et al.
In contact brachytherapy, skin and subcutaneous tissue receive significantly higher doses than the prescribed dose as the dose is typically prescribed to a depth of 5 to 7 mm. We used CT-based planning and optimization, and the skin was excluded from the reference dose. Additionally, a maximum 10 mm distance was allowed between the lateral tube and the reference isodose line in order to avoid very high dose regions within the target. This could explain the low rate of late ≥grade 3 toxicities (5/56, 8.9%) among our patients compared to other radiation techniques used for reirradiation, including contact brachytherapy. The sharp dose gradient of HDR-IRT resulted in a low mean dose to the ipsilateral lung (3.2 Gy). Likewise, the mean dose to the heart in left-sided tumors was significantly low (2.8 Gy). Among our patients, there was no observed radiation-induced heart or lung disease. Studies that used different EBRT techniques for reirradiation did not discuss the incidence of such complications.
The approach of combining local surgery with interstitial HDR-IRT as a salvage option for tumor recurrences after previous irradiation has been investigated in different tumor entities [14,15,26,27,28,29]. In a large matched cohort analysis of the GEC-ESTRO, combining both local surgery and interstitial HDR-IRT as a salvage management for ipsilateral recurrence of breast cancer following conservative breast therapy resulted in similar oncological outcomes compared to salvage mastectomy [30]. In the present study, the combined approach of macroscopic resection of the LR followed by HDR-IRT resulted in 82% 5-year local recurrence-free survival, which is higher than the local control rates reported by other studies.
5. Conclusions
Salvage perioperative interstitial high-dose-rate interventional radiotherapy (brachytherapy) combined with surgery seems to be a feasible and effective interdisciplinary management for local recurrences of the chest wall following mastectomy and previous external irradiation. Intraoperative target definition and clip documentation, as well as CT-based personalized dose optimization and dose painting using the stepping-source technology, offer good target coverage and spares organs at risk, which consequently leads to good local control rates and acceptable treatment-related toxicity.
Author Contributions
Conceptualization, G.K. and T.S.; methodology, T.S. and M.B.-P.; validation, data collection, M.B.-P., K.M., M.X., C.M. and T.S.; formal analysis, T.S.; investigation, T.S. and M.B.-P.; resources, T.S. and M.B.-P.; data curation, T.S., C.M. and M.B.-P.; writing—original draft preparation, T.S.; writing—review and editing, all authors; visualization, T.S.; supervision, D.R., A.R. and G.K.; project administration, T.S. and M.B.-P. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of University of Lübeck (protocol code 2022-510, date of approval: 13 October 2022.) All patients signed an informed consent before treatment.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available in this article.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Bedwinek, J. Natural History and Management of Isolated Local-Regional Recurrence Following Mastectomy. Semin. Radiat. Oncol. 1994, 4, 260–269. [Google Scholar] [CrossRef] [PubMed]
- Buchanan, C.L.; Dorn, P.L.; Fey, J.; Giron, G.; Naik, A.; Mendez, J.; Murphy, C.; Sclafani, L.M. Locoregional Recurrence after Mastectomy: Incidence and Outcomes. J. Am. Coll. Surg. 2006, 203, 469–474. [Google Scholar] [CrossRef] [PubMed]
- McGale, P.; Taylor, C.; Correa, C.; Cutter, D.; Duane, F.; Ewertz, M.; Gray, R.; Mannu, G.; Peto, R.; Whelan, T.; et al. Effect of Radiotherapy after Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality: Meta-Analysis of Individual Patient Data for 8135 Women in 22 Randomised Trials. Lancet 2014, 383, 2127–2135. [Google Scholar] [CrossRef] [PubMed]
- Nielsen, H.M.; Overgaard, M.; Grau, C.; Jensen, A.R.; Overgaard, J. Study of Failure Pattern among High-Risk Breast Cancer Patients with or without Postmastectomy Radiotherapy in Addition to Adjuvant Systemic Therapy: Long-Term Results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c Randomized Studies. J. Clin. Oncol. 2006, 24, 2268–2275. [Google Scholar] [CrossRef] [Green Version]
- Fattahi, S.; Ahmed, S.K.; Park, S.S.; Petersen, I.A.; Shumway, D.A.; Stish, B.J.; Yan, E.S.; Remmes, N.B.; Mutter, R.W.; Corbin, K.S. Reirradiation for Locoregional Recurrent Breast Cancer. Adv. Radiat. Oncol. 2020, 6, 100640. [Google Scholar] [CrossRef]
- Marta, G.N.; Hijal, T.; de Andrade Carvalho, H. Reirradiation for Locally Recurrent Breast Cancer. Breast 2017, 33, 159–165. [Google Scholar] [CrossRef]
- Harms, W.; Krempien, R.; Grehn, C.; Hensley, F.; Berns, C.; Wannenmacher, M.; Debus, J. Reirradiation of Chest Wall Local Recurrences from Breast Cancer. Zentralbl. Gynakol. 2004, 126, 19–23. [Google Scholar] [CrossRef]
- De-Colle, C.; Weidner, N.; Heinrich, V.; Brucker, S.; Hahn, M.; MacMillan, K.; Lamprecht, U.; Gaupp, S.; Voigt, O.; Zips, D. Hyperthermic Chest Wall Re-Irradiation in Recurrent Breast Cancer: A Prospective Observational Study. Strahlenther. Onkol. 2019, 195, 318–326. [Google Scholar] [CrossRef]
- Oldenborg, S.; Rasch, C.R.N.; van Os, R.; Kusumanto, Y.H.; Oei, B.S.; Venselaar, J.L.; Heymans, M.W.; zum Vörde Sive Vörding, P.J.; Crezee, H.; van Tienhoven, G. Reirradiation + Hyperthermia for Recurrent Breast Cancer En Cuirasse. Strahlenther. Onkol. 2018, 194, 206–214. [Google Scholar] [CrossRef] [Green Version]
- Besson, N.; Hennequin, C.; Guillerm, S.; Fumagalli, I.; Martin, V.; Michaud, S.; Texeira, L.; Quero, L. Plesiobrachytherapy for Chest Wall Recurrences of Breast Cancer after Mastectomy and Radiotherapy for Breast Cancer. Brachytherapy 2018, 17, 425–431. [Google Scholar] [CrossRef]
- Auoragh, A.; Strnad, V.; Ott, O.J.; Beckmann, M.W.; Fietkau, R. Re-Irradiation of the Chest Wall for Local Breast Cancer Recurrence: Results of Salvage Brachytherapy with Hyperthermia. Strahlenther. Onkol. 2016, 192, 617–623. [Google Scholar] [CrossRef] [PubMed]
- Harms, W.; Krempien, R.; Hensley, F.W.; Berns, C.; Wannenmacher, M.; Fritz, P. Results of Chest Wall Reirradiation Using Pulsed-Dose-Rate (PDR) Brachytherapy Molds for Breast Cancer Local Recurrences. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 205–210. [Google Scholar] [CrossRef] [PubMed]
- Mayer, Á.; Naszály, A.; Patyánik, M.; Zaránd, P.; Polgár, I.; Klinkó, T. Perioperative Brachytherapy for Pretreated Chest Wall Recurrence of Breast Cancer. Strahlenther. Onkol. 2002, 178, 633–636. [Google Scholar] [CrossRef] [PubMed]
- Niehoff, P.; Dietrich, J.; Ostertag, H.; Schmid, A.; Kohr, P.; Kimmig, B.; Kovács, G. High-Dose-Rate (HDR) or Pulsed-Dose-Rate (PDR) Perioperative Interstitial Intensity-Modulated Brachytherapy (IMBT) for Local Recurrences of Previously Irradiated Breast or Thoracic Wall Following Breast Cancer. Strahlenther. Onkol. 2006, 182, 102–107. [Google Scholar] [CrossRef] [PubMed]
- Khan, N.; Clemens, M.; Liu, J.; Garden, A.S.; Lawyer, A.; Weber, R.; Gunn, G.B.; Morrison, W.H.; Kupferman, M.E. The Role of Salvage Surgery with Interstitial Brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. Cancers Head Neck 2019, 4, 4. [Google Scholar] [CrossRef]
- Soror, T.; Kovács, G.; Fürschke, V.; Ismail, M.; Badakhshi, H. Salvage Treatment with Sole High-Dose-Rate Endobronchial Interventional Radiotherapy (Brachytherapy) for Isolated Endobronchial Tumor Recurrence in Non-Small-Cell Lung Cancer Patients: A 20-Year Experience. Brachytherapy 2019, 18, 727–732. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.P.; Weinberg, V.; Shinohara, K.; Roach, M.; Nash, M.; Gottschalk, A.; Chang, A.J.; Hsu, I.C. Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 324–329. [Google Scholar] [CrossRef]
- Chest Wall Resection in the Treatment of Locally Recurrent Breast Carcinoma: Indications and Outcome for 44 Patients. Available online: https://pubmed.ncbi.nlm.nih.gov/9307188/ (accessed on 25 November 2022).
- van der Pol, C.C.; van Geel, A.N.; Menke-Pluymers, M.B.E.; Schmitz, P.I.M.; Lans, T.E. Prognostic Factors in 77 Curative Chest Wall Resections for Isolated Breast Cancer Recurrence. Ann. Surg. Oncol. 2009, 16, 3414–3421. [Google Scholar] [CrossRef] [Green Version]
- Wahl, A.O.; Rademaker, A.; Kiel, K.D.; Jones, E.L.; Marks, L.B.; Croog, V.; McCormick, B.M.; Hirsch, A.; Karkar, A.; Motwani, S.B.; et al. Multi-Institutional Review of Repeat Irradiation of Chest Wall and Breast for Recurrent Breast Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 477–484. [Google Scholar] [CrossRef]
- Oldenborg, S.; Griesdoorn, V.; van Os, R.; Kusumanto, Y.H.; Oei, B.S.; Venselaar, J.L.; zum Vörde Sive Vörding, P.J.; Heymans, M.W.; Kolff, M.W.; Rasch, C.R.N.; et al. Reirradiation and Hyperthermia for Irresectable Locoregional Recurrent Breast Cancer in Previously Irradiated Area: Size Matters. Radiother. Oncol. 2015, 117, 223–228. [Google Scholar] [CrossRef]
- Marples, B.; Collis, S.J. Low-Dose Hyper-Radiosensitivity: Past, Present, and Future. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 1310–1318. [Google Scholar] [CrossRef] [PubMed]
- Burr, A.R.; Robins, H.I.; Bayliss, R.A.; Howard, S.P. Pulsed Reduced Dose Rate for Reirradiation of Recurrent Breast Cancer. Pract. Radiat. Oncol. 2020, 10, e61–e70. [Google Scholar] [CrossRef] [PubMed]
- LaRiviere, M.J.; Dreyfuss, A.; Taunk, N.K.; Freedman, G.M. Proton Reirradiation for Locoregionally Recurrent Breast Cancer. Adv. Radiat. Oncol. 2021, 6, 100710. [Google Scholar] [CrossRef] [PubMed]
- Choi, J.I.; Khan, A.J.; Powell, S.N.; McCormick, B.; Lozano, A.J.; del Rosario, G.; Mamary, J.; Liu, H.; Fox, P.; Gillespie, E.; et al. Proton Reirradiation for Recurrent or New Primary Breast Cancer in the Setting of Prior Breast Irradiation. Radiother. Oncol. 2021, 165, 142–151. [Google Scholar] [CrossRef]
- Harms, W.; Budach, W.; Dunst, J.; Feyer, P.; Fietkau, R.; Haase, W.; Krug, D.; Piroth, M.D.; Sautter-Bihl, M.L.; Sedlmayer, F.; et al. DEGRO Practical Guidelines for Radiotherapy of Breast Cancer VI: Therapy of Locoregional Breast Cancer Recurrences. Strahlenther. Onkol. 2016, 192, 199–208. [Google Scholar] [CrossRef] [Green Version]
- Smanykó, V.; Mészáros, N.; Újhelyi, M.; Fröhlich, G.; Stelczer, G.; Major, T.; Mátrai, Z.; Polgár, C. Second Breast-Conserving Surgery and Interstitial Brachytherapy vs. Salvage Mastectomy for the Treatment of Local Recurrences: 5-Year Results. Brachytherapy 2019, 18, 411–419. [Google Scholar] [CrossRef]
- Teudt, I.U.; Kovàcs, G.; Ritter, M.; Melchert, C.; Soror, T.; Wollenberg, B.; Meyer, J.E. Intensity Modulated Perioperative HDR Brachytherapy for Recurrent and/or Advanced Head and Neck Metastases. Eur. Arch. Otorhinolaryngol. 2016, 273, 2707–2715. [Google Scholar] [CrossRef]
- Quivrin, M.; Peignaux-Casasnovas, K.; Martin; Rouffiac, M.; Thibouw, D.; Chevalier, C.; Vulquin, N.; Aubignac, L.; Truc, G.; Créhange, G. Salvage Brachytherapy as a Modern Reirradiation Technique for Local Cancer Failure: The Phoenix Is Reborn from Its Ashes. Cancer Radiother. 2018, 22, 372–381. [Google Scholar] [CrossRef]
- Hannoun-Levi, J.M.; Gal, J.; van Limbergen, E.; Chand, M.E.; Schiappa, R.; Smanyko, V.; Kauer-Domer, D.; Pasquier, D.; Lemanski, C.; Racadot, S.; et al. Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 452–461. [Google Scholar] [CrossRef]
Figure 1.
(a) and (b): intraoperative catheter implantation and suturing; (c): during the irradiation; (d): 5 years after high-dose-rate interventional radiotherapy.
Figure 1.
(a) and (b): intraoperative catheter implantation and suturing; (c): during the irradiation; (d): 5 years after high-dose-rate interventional radiotherapy.
Figure 2.
Representative samples of the dose distribution: (a): transversa; (b): sagittal; (c): coronal; (d): three-dimensional reconstruction. Green: clinical target volume; yellow: rips; orange: heart; red: reference isodose line.
Figure 2.
Representative samples of the dose distribution: (a): transversa; (b): sagittal; (c): coronal; (d): three-dimensional reconstruction. Green: clinical target volume; yellow: rips; orange: heart; red: reference isodose line.
Figure 3.
(a) Overall survival; (b) local recurrence-free survival.
Table 1.
Patients and disease characteristics.
| Characteristic | Value | Number (%) |
|---|---|---|
| Initial T stage | T0 T1 T2 T3 T4 Unknown | 1 (1.8%) 11 (19.6%) 22 (39.3%) 4 (7.1%) 6 (10.7%) 12 (21.4%) |
| T stage at salvage treatment | T1 T2 T3 T4 | 19 (33.9%) 32 (57.1%) 3 (5.4%) 2 (3.6%) |
| Initial lymph node status | Negative Positive Unknown | 20 (35.7%) 24 (42.9%) 12 (21.4%) |
| Histology type | Ductal carcinoma in situ Non-special type Lobular carcinoma Other | 1 (1.8%) 39 (69.6%) 9 (16.1%) 7 (12.5%) |
| Initial histologic grade | Grade 1 Grade 2 Grade 3 Unknown | 3 (5.4%) 21 (37.5%) 17 (30.4%) 15 (26.7%) |
| Histologic grade at salvage treatment | Grade 1 Grade 2 Grade 3 | 3 (5.4%) 27 (48.2%) 26 (46.4%) |
| Initial surgical margin status | Negative Positive | 56 (100%) 0 (0%) |
| Surgical margin status at salvage treatment | Negative Positive | 51 (47.1%) 5 (8.9) |
| Estrogen/progesterone receptor status | Positive Negative Unknown | 39 (69.6%) 12 (21.4%) 5 (8.9%) |
| HER2-status | Positive Negative Unknown | 22 (39.3%) 28 (50%) 6 (10.7%) |
| Primary surgical operation | Mastectomy Breast conserving surgery | 43 (75.4%) 14 (24.6%) |
| Previous hormonal treatment | 39 (69.6%) | |
| Previous chemotherapy | 43 (76.8%) |
Table 2.
Dosimetry parameters of the HDR-IRT.
| Parameter | Median (Range) |
|---|---|
| HDR-IRT dose Total dose Dose per fraction Number of fractions | 30 Gy (25–36) 2.5 Gy (2.5–4) 10 (8–12) |
| Clinical target volume (CTV) | |
| Volume D90% V100% V150% | 25.5 cc (16–46) 93.8% (89.5–102) 87.2% (84.3–92.8) 37.2% (33.1–42.2) |
| Ipsilateral lung mean dose | 3.2% (2.7–3.8) |
| Heart mean dose (in left-sided tumors) | 2.8% (2.2–3.3) |
HDR-IRT: high-dose-rate interventional radiotherapy; Gy: Gray; cc: cubic centimeter; D90%: the dose in percentage that covers 90% of CTV; V100: the volume in percentage that is receives 100% of the prescribed dose; V150%: the volume in percentage that receives 150% of the prescribed dose.
Table 3.
Treatment-related toxicities.
| Encountered Toxicity | Number (%) | Severity |
|---|---|---|
| Acute radiation dermatitis | 22 (39.3%) | Grade 1–2 |
| Late skin toxicities | 19 (33.9%) | Grade 1–2 |
| Fibrosis | 14 (25%) 3 (5.4%) | Grade 1–2 Grade ≥3 |
| Chronic wound complications | 1 (1.8%) | Grade ≥3 |
| Necrosis | 1 (1.8%) | Grade ≥3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Soror, T.; Banys-Paluchowski, M.; Melchert, C.; Rades, D.; Rody, A.; Muras, K.; Xie, M.; Kovács, G. Salvage Perioperative Interstitial High-Dose-Rate Interventional Radiotherapy (Brachytherapy) for Local Recurrences of the Chest Wall Following Mastectomy and Previous External Irradiation. Cancers 2023, 15, 614. https://doi.org/10.3390/cancers15030614
AMA Style
Soror T, Banys-Paluchowski M, Melchert C, Rades D, Rody A, Muras K, Xie M, Kovács G. Salvage Perioperative Interstitial High-Dose-Rate Interventional Radiotherapy (Brachytherapy) for Local Recurrences of the Chest Wall Following Mastectomy and Previous External Irradiation. Cancers. 2023; 15(3):614. https://doi.org/10.3390/cancers15030614
Chicago/Turabian StyleSoror, Tamer, Maggie Banys-Paluchowski, Corinna Melchert, Dirk Rades, Achim Rody, Kerstin Muras, Meiting Xie, and György Kovács. 2023. "Salvage Perioperative Interstitial High-Dose-Rate Interventional Radiotherapy (Brachytherapy) for Local Recurrences of the Chest Wall Following Mastectomy and Previous External Irradiation" Cancers 15, no. 3: 614. https://doi.org/10.3390/cancers15030614
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
